KRG launches new Tendering Process for Medicines

By John Lee.

The Kurdistan Regional Government (KRG) has announced a new tendering process for medicines.

According to a statement from the KRG, the new system will stabilise the price of 230 different medications.

KRG Prime Minister Masrour Barzani commented:

“Through transparent contracts, we will provide our citizens with better quality medicine at a lower cost to the KRG.”

More here and here.

(Source: KRG)

The post KRG launches new Tendering Process for Medicines first appeared on Iraq Business News.

Iraq’s Locally Made Hand Sanitizer and Disinfectant

The University of Karbala produces locally made hand sanitizer and disinfectant for health facilities, in first of its kind UNICEF-supported project

In the first of its kind project since the corona virus outbreak, graduate students in the pharmaceutical department of the University of Karbala have produced 14,500 locally made hand sanitizers and 10,000 large products to disinfect surfaces, with the support of UNICEF and its partner the Karbala Directorate of Health.

Over the course of the month of June, the bottles were distributed to primary healthcare centers in Karbala and Baghdad, both which have been hard hit by covid19.

“We have been distributing hand sanitizer and soap to some of the most vulnerable communities since the beginning of the outbreak. To now be able to support Iraqis as they themselves produce items they need to protect their communities from COVID-19 is something we are proud of and that lives up to our commitment to empower local communities who are driving positive change,” said Hamida Lasseko, UNICEF’s Representative in Iraq.

The sanitizer is produced according to the highest global standards and with locally sourced raw materials. The gel is then bottled into 250 milliliters containers that are labelled and include instructions on how to use. The production cost of one bottle amounts 2 US dollars, a third of the average selling price of one hand sanitizer bottle (6 dollars) on the market.

“I am happy with the quality of the materials that we are using. I hope that our work will benefit Iraqis across the country, and not only here in Karbala,” explained Karrar Abd, one of the graduate students taking part in the production.

There are already plans to produce at least 10,000 more bottles that will be distributed in the two governorates, as well as in Basra and Najaf. The production process takes up to three weeks. Once ready, youth volunteers who are trained in hygiene promotion by UNICEF distribute the bottles to public health clinics and centers. To date, the hand sanitizer bottles, and disinfectant solution have been given to 34 main Primary health care centers in Karbala and Baghdad.

“I heard so many people say that COVID-19 does not exist, which is not true. Someone in my family came into contact with the disease and transmitted it on to others. I know that hand sanitizer is the best way to prevent us from spreading COVID-19 because it ensures that we have clean hands, and therefore I wanted to work on this project. It makes me feel I am giving something to my community,” explained 22-year old Zainab Hussein, one of the volunteers from Karbala who participated in the distributing.

With access to hand sanitizer, patients and health workers alike can practice hand hygiene, thereby enabling health centers to continue providing communities with essential services such as immunization and maternal health despite COVID-19. The project was made possible with generous support of the Department of International Development (DFID UK).

(Source: UN)

Pharma Firm pays $25m to Resolve Corrupt Payments

The US Securities and Exchange Commission (SEC) announced that Paris-based pharmaceutical company Sanofi has agreed to pay more than $25 million to resolve charges that its Kazakhstan and the Middle East subsidiaries made corrupt payments to win business.

According to the SEC’s order, the schemes spanned multiple countries and involved bribe payments to government procurement officials and healthcare providers in order to be awarded tenders and to increase prescriptions of its products.

In the Middle East, various pay-to-prescribe schemes were used to induce healthcare providers to increase their prescriptions of Sanofi products.

In Iraq, for example, a healthcare professional (HCP) requesting samples of Taxotere in 2012 was also provided with consulting, speaking, and clinical trial fees over a period of years despite the lack of documentation of other support to demonstrate the services had been provided. Sanofi paid to the HCP the equivalent in local currency of USD 28,900 in consulting fees and, USD 5500 in speaking fees.

Sanofi also paid to the HCP USD 125,997 in clinical trial fees. The consulting fees were purportedly related to hosting events and training for HCPs in Iraq. No supporting documentation was found for any of the purported consultancy services. While the clinical trial fees were approved by Medical Affairs, the HCP has never provided reports of findings or observations.

The HCP, who provided the ostensible speaking, consulting, and clinical trial services to Sanofi, requested that the consulting and clinical trial fees be paid by check to an unrelated individual.

Sanofi accommodated the request to pay the unrelated individual without explanation or justification.

“Bribery in connection with pharmaceutical sales remains as a significant problem despite numerous prior enforcement actions involving the industry and life sciences more generally,” said Charles Cain, FCPA Unit Chief, SEC Enforcement Division. “While bribery risk can impact any industry, this matter illustrates that more work needs to be done to address the particular risks posed in the pharmaceutical industry.”

The SEC’s order finds that Sanofi violated the books and records and internal accounting controls provisions of the federal securities laws. Without admitting or denying the findings, Sanofi agreed to a cease-and-desist order and to pay $17.5 million in disgorgement, $2.7 million in prejudgment interest, and a civil penalty of $5 million.

The SEC appreciates the assistance of Fraud Section of the Department of Justice, the Federal Bureau of Investigation, and the Autorité des marchés financiers in France.

(Source: SEC)

AstraZeneca Investigated for Alleged Corruption in Iraq

By John Lee.

UK-bassed pharmaceutical company AstraZeneca has said it is the subject of an anti-corruption investigation in the US relating to its activities in Iraq

In its latest quarterly filing with the Securities and Exchange Commission (SEC), the company said:

As previously disclosed, in the US, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device companies were named as defendants in a complaint filed in federal court in the District of Columbia by US nationals (or their estates, survivors, or heirs) who were killed or wounded in Iraq between 2005 and 2009 (the Lawsuit).

“The plaintiffs allege that the defendants violated the US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of Health.

“In addition, AstraZeneca has received an inquiry from the US Department of Justice in connection with an anti-corruption investigation relating to activities in Iraq, including interactions with the Iraqi government and certain of the same matters alleged in the Lawsuit.

(Source: AstraZeneca)

Investment Opportunity: Pharmaceutical Plant in Samarra

By John Lee.

The National Investment Commission (NIC), and the State Company for Drugs and Medical Appliances, have announced an opportunity to invest in the rehabilitation, modernization and operation of the Samarra drugs plant.

In a statement, the NIC said:

It invites reliable Arab and foreign companies directly or their agents – not mediator or supported – to participate in this investment opportunity to rehabilitate and modernize this plant on basisof participating in management, production, increasing the production capacities and take pasrt in this valuable opportunity to satisfy the Iraqi market demands and for the economic feasibility and the realizable privileges for the investors such as the availability of the essential materials for production .

“Willing investors can obtain the investment profile from the company HQ in Samarra as per the companies law no. 22 for the year 1997 as amended, article 15/3rd ; for an amount of (500,000) IDR non- refundable.

“The company shall offer all detailed information and facilitate the visit to the plan. Applications shall be according to the terms stated in the investment profile , provided that applications should be submitted by a sealed envelope before the end of the work time of Thursday 12.07.2018.

You may also visit the website www.sdisamarra.com

More details can be downloaded here (English from page 43)

(Source: National Investment Commission)